T1	p 85 116	invasive diarrhea in children .
T2	p 190 198	children
T3	p 369 402	acute invasive diarrhea requiring
T4	p 425 440	southern Israel
T5	p 714 761	diarrhea in infants and children . PATIENTS AND
T6	p 770 969	From July 1996 through December 1997 , 201 evaluable children ages 6 months to 10 years ( 35 % < 1 year ; 70 % < 3 years ) presenting with acute invasive diarrhea at the Pediatric Emergency Room were
T7	p 1462 1470	patients
T8	p 2423 2488	ambulatory pediatric patients requiring an emergency room visit .
T9	i 6 65	Oral ciprofloxacin vs. intramuscular ceftriaxone as empiric
T10	i 281 320	antibiotics , intramuscular ceftriaxone
T11	i 665 678	ciprofloxacin
T12	i 999 1025	ciprofloxacin suspension (
T13	i 1043 1063	day + im placebo ; n
T14	i 1071 1124	or im ceftriaxone ( 50 mg/kg/day + placebo suspension
T15	i 1485 1493	Shigella
T16	i 1803 1816	ciprofloxacin
T17	i 1821 1832	ceftriaxone
T18	i 1863 1876	ciprofloxacin
T19	i 2110 2123	ciprofloxacin
T20	i 2138 2149	ceftriaxone
T21	i 2293 2311	Oral ciprofloxacin
T22	i 2355 2366	ceftriaxone
T23	o 79 102	acute invasive diarrhea
T24	o 134 151	invasive diarrhea
T25	o 227 261	resistance of enteric pathogens to
T26	o 384 392	diarrhea
T27	o 576 584	diarrhea
T28	o 614 633	efficacy and safety
T29	o 705 722	invasive diarrhea
T30	o 924 932	diarrhea
T31	o 1325 1353	Clinical response and safety
T32	o 1430 1443	127 pathogens
T33	o 1575 1608	Overall bacteriologic eradication
T34	o 1738 1766	Clinical cure or improvement
T35	o 1857 1883	Serum ciprofloxacin values
T36	o 2056 2083	drug-related adverse events
T37	o 2184 2213	transient . Joint examination
T38	o 2396 2419	acute invasive diarrhea
T39	o 2423 2433	ambulatory